Overview of paclitaxel (TAXOL®) in advanced lung cancer

Research output: Contribution to journalArticlepeer-review


Paclitaxel (TAXOL®), a novel diterpene plant product isolated from the western yew Taxus brevifolia, is an active agent in the treatment of lung cancer. In two studies, the drug produced 21% and 24% objective response rates among patients with non-small cell lung cancer. A response rate of 34% was reported in a single trial involving patients with extensive-stage small cell lung cancer. Additional trials are needed to evaluate single-agent paclitaxel in the treatment of small cell lung cancer. Studies also are planned to measure the effect of paclitaxel as a radiosensitizer and in combination regimens with other active agents for the treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)46-49
Number of pages4
JournalSeminars in oncology
Issue number4 SUPPL. 3
StatePublished - Aug 23 1993

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Overview of paclitaxel (TAXOL®) in advanced lung cancer'. Together they form a unique fingerprint.

Cite this